Danske Bank’s Xeris Biopharma Holdings XERS Stock Holding History

Danske Bank’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$6	–	1672
2024 Q3	$6	Buy	+2	New	+$5	﹤0.01%	1549

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Danske Bank's XERS Position: Q4 2024 in Review

Danske Bank sold out of Xeris Biopharma Holdings (XERS) in Q4 2024, closing a stake of 2 shares — an estimated $6 sold.

Danske Bank first reported a position in XERS in Q3 2024 and held it in 1 quarter. The position peaked at $6 in Q3 2024. 162 funds tracked by Wall St. Rank hold XERS as of Q4 2024.

Danske Bank reported no remaining Xeris Biopharma Holdings position as of Q4 2024 after selling out during the quarter.
Danske Bank sold 2 Xeris Biopharma Holdings shares in Q4 2024, an estimated $6.
Danske Bank first reported a position in Xeris Biopharma Holdings in Q3 2024 and held it in 1 quarter.
Danske Bank's Xeris Biopharma Holdings position peaked at $6 in Q3 2024.
162 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.